PT Medela Potentia Tbk Records Double-Digit Profit Growth in 2025

PT Medela Potentia Tbk (MDLA) recorded solid financial performance throughout the 2025 fiscal year amid the dynamics of Indonesia’s healthcare industry. The Company posted double-digit net profit growth of 16 percent year-on-year, reaching IDR 398.1 billion, supported by revenue growth to IDR 14.89 trillion.

President Director of PT Medela Potentia Tbk, Krestijanto Pandji, stated that the achievement reflects the Company’s strong business fundamentals, supported by strengthened distribution systems and operational optimization.

“Double-digit net profit growth is a positive indicator of the Company’s performance throughout 2025. Going forward, the Company will remain focused on maintaining stable growth through strengthening logistics infrastructure and optimizing its business portfolio,” he said.

Throughout 2025, the Company strengthened its business portfolio by adding eight new principals, consisting of two prescription pharmaceutical principals, two consumer health principals, and four medical device principals. This diversification is expected to enhance the range of distribution solutions offered while strengthening the Company’s competitiveness in the healthcare industry.

On the infrastructure front, the Company continued to enhance its distribution capabilities as part of its strategy to increase capacity and operational efficiency. In May 2025, the Company acquired National Distribution Center (NDC) 1, covering an area of 10,000 square meters with a capacity of 13,525 pallets, located in Jababeka Industrial Estate II, Cikarang, West Java. The facility has been an integral part of the Company’s distribution infrastructure for more than 10 years and was previously utilized under a lease arrangement from an affiliated company.

In addition, the Company acquired a 2.7-hectare land plot in Jababeka Industrial Estate I, which is planned for the development of NDC 2 of PT Anugrah Argon Medica. This expansion will further strengthen warehouse capabilities while improving service speed and quality for customers.

To expand distribution reach in the Sumatra region, the construction of a warehouse and branch office of PT Anugrah Argon Medica in Medan is targeted for completion by the end of 2026.

In the medical device segment, the Company’s subsidiary, PT Deca Metric Medica (DMM), began expanding into international markets by exporting medical devices to Cambodia and Timor-Leste in August 2025.

Meanwhile, another subsidiary focusing on medical device marketing, PT Djembatan Dua, continued to strengthen its own-brand portfolio by launching three new product SKUs, supporting total sales growth of 50%.

In the digital business line, the GoApotik platform recorded revenue growth of 32%, with a 24% increase in customer transactions compared to the previous year.

In addition to business growth, the Company continued to implement Environmental, Social, and Governance (ESG) principles across its operations. Through the Argon Peduli program, various social initiatives reached 23,488 beneficiaries throughout 2025.

These initiatives included free health check-up services, community health post (posyandu) development, educational scholarships, and stunting prevention programs.

The Company also collaborated with regulators to promote Good Distribution Practices (CDOB) as part of its contribution to improving healthcare service quality in Indonesia.

On the environmental front, the Company has implemented the use of electric motorcycles for operational activities to support energy efficiency and reduce carbon emissions. As of the end of 2025, electric motorcycles have been deployed across 15 branches in 13 cities, totaling 106 units.

These achievements reflect the Company’s commitment to good corporate governance, continuous innovation, and building a sustainable organization. Throughout 2025, the Company also received various awards for its ESG practices, digital innovation, and human capital development.